


This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

Claim 1 (canceled)

Claim 2 (currently amended): ~~The method of Claim 1~~ A method for the prophylaxis or treatment of a hyperlipidemic condition or disorder in a subject, said method comprising administering a first amount of an apical sodium co-dependent bile acid transporter inhibitor and a second amount of an HMG Co-A reductase inhibitor, wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claims 3-15 (canceled)

Claim 16 (currently amended): The method of Claim 1 2 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, atorvastatin, ~~ZD-4522~~ rosuvastatin, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

Claim 17 (currently amended): The method of Claim + 16 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin, ~~ZD-4522~~ rosuvastatin, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

Claim 18 (currently amended): The method of Claim + 16 wherein the HMG Co-A reductase inhibitor comprises mevastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 19 (currently amended): The method of Claim + 17 wherein the HMG Co-A reductase inhibitor comprises atorvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 20 (currently amended): The method of Claim + 17 wherein the HMG Co-A reductase inhibitor comprises simvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 21 (currently amended): The method of Claim + 17 wherein the HMG Co-A reductase inhibitor comprises pravastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 22 (currently amended): The method of Claim + 16 wherein the HMG Co-A reductase inhibitor comprises lovastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 23 (currently amended): The method of Claim + 16 wherein the HMG Co-A reductase inhibitor comprises cerivastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.


Claim 24 (currently amended): The method of Claim + 16 wherein the HMG Co-A reductase inhibitor comprises fluvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 25 (currently amended): The method of Claim 1 ~~17~~ wherein the HMG Co-A reductase inhibitor comprises ~~ZD-4522~~ rosuvastatin, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

Claim 26 (currently amended): The method of Claim 1 ~~2~~ wherein the HMG Co-A reductase inhibitor comprises ~~NK-104~~ pitavastatin, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

Claims 27-28 (canceled)

Claim 29 (currently amended): ~~The method of Claim 27~~ A method for the prophylaxis or treatment of a hyperlipidemic condition or disorder in a subject, said method comprising administering a first amount of an apical sodium co-dependent bile acid transporter inhibitor and a second amount of an HMG Co-A reductase inhibitor, wherein the apical sodium co-dependent bile acid transporter inhibitor comprises the racemate of



or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claims 30-39 (canceled)

Claim 40 (currently amended): The method of claim 28 2 wherein the apical sodium co-dependent bile acid transporter inhibitor and the HMG Co-A reductase inhibitor are administered in a sequential manner.

Claim 41 (currently amended): The method of claim 28 2 wherein the apical sodium co-dependent bile acid transporter inhibitor and the HMG Co-A reductase inhibitor are administered in a substantially simultaneous manner.

Claim 42 (currently amended): The method of claim 28 2 wherein the weight ratio of apical sodium co-dependent bile acid transporter inhibitor to HMG Co-A reductase inhibitor administered is between about 1:50 to about 3:1.


Claim 43 (currently amended): The method of claim 28 2 wherein said apical sodium co-dependent bile acid transporter inhibitor is administered in a daily dose ranging from about 0.008 mg to about 100 mg, and said HMG Co-A reductase inhibitor is administered in a daily dose ranging from about 0.05 mg to about 100 mg.

Claim 44 (currently amended): The method of claim 28 2 wherein said apical sodium co-dependent bile acid transporter inhibitor is administered in a daily dose range from about 0.08 0.008 mg to about 100 mg.

Claim 45 (currently amended): The method of claim 28 2 wherein the HMG Co-A reductase inhibitor is administered in a daily dose range from about 0.05 mg to about 100 mg.

Claim 46 (cancelled)

Claim 47 (currently amended): ~~The composition of Claim 46 wherein the~~ A composition comprising a first amount of an apical sodium co-dependent bile acid transporter inhibitor ~~comprises comprising~~



or a pharmaceutically acceptable salt, ester or prodrug thereof;
a second amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof; and
a pharmaceutically acceptable carrier;
wherein the first and second amounts of said inhibitors together comprise a therapeutically effective amount of said inhibitors.

Claims 48-60 (cancelled)

Claim 61 (currently amended): The composition of Claim 46 47 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, atorvastatin, ~~ZD-4522~~ rosuvastatin, NK-104 pitavastatin, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

Claim 62 (currently amended): The composition of Claim 46 61 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin,

~~ZD-4522~~ rosuvastatin, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

Claim 63 (currently amended): The composition of Claim 46 ~~61~~ wherein the HMG Co-A reductase inhibitor comprises mevastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 64 (currently amended): The composition of Claim 46 ~~62~~ wherein the HMG Co-A reductase inhibitor comprises atorvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 65 (currently amended): The composition of Claim 46 ~~62~~ wherein the HMG Co-A reductase inhibitor comprises simvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 66 (currently amended): The composition of Claim 46 ~~62~~ wherein the HMG Co-A reductase inhibitor comprises pravastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 67 (currently amended): The composition of Claim 46 ~~61~~ wherein the HMG Co-A reductase inhibitor comprises lovastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.


Claim 68 (currently amended): The composition of Claim 46 ~~61~~ wherein the HMG Co-A reductase inhibitor comprises cerivastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 69 (currently amended): The composition of Claim 46 61 wherein the HMG Co-A reductase inhibitor comprises fluvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 70 (currently amended): The composition of Claim 46 62 wherein the HMG Co-A reductase inhibitor comprises ~~ZD-4522~~ rosuvastatin, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

Claim 71 (currently amended): The composition of Claim 46 61 wherein the HMG Co-A reductase inhibitor comprises ~~NK-104~~ pitavastatin, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

Claim 72 (currently amended): ~~The composition of Claim 46 wherein the~~ A composition comprising a first amount of an apical sodium co-dependent bile acid transporter inhibitor ~~comprises~~ comprising the racemate of



or a pharmaceutically acceptable salt, ester or prodrug thereof; and


the an HMG Co-A reductase inhibitor is selected from the group consisting of mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, atorvastatin, ~~ZD-4522~~ rosuvastatin, ~~NK-104~~ pitavastatin, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

Claims 73-83 (canceled)

Claim 84 (currently amended): The composition of claim ~~73~~ 47 wherein the weight ratio of apical sodium co-dependent bile acid transporter inhibitor to HMG Co-A reductase inhibitor is between about 1:50 to about 3:1.

Claim 85 (canceled)

Claim 86 (currently amended): ~~A kit of Claim 85~~ A kit containing a first dosage form comprising an apical sodium co-dependent bile acid transporter inhibitor and a second dosage form comprising an HMG Co-A reductase inhibitor wherein the apical sodium co-dependent bile acid transporter inhibitor comprises ~~the 4R,5R enantiomer of~~



or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claim 87 (currently amended): ~~A~~ The kit of Claim 86 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, atorvastatin, ~~ZD-4522~~ rosuvastatin, ~~NK-104~~ pitavastatin, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

Claim 88 (currently amended): A The kit of Claim ~~86~~ 87 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin, ~~ZD-4522~~ rosuvastatin, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

Claim 89 (canceled)